{"filing":{"accession_number":"0001903596-26-000287","cik":"0001497130","ticker":null,"company_name":"Nano Mobile Healthcare, Inc.","form":"8-K","filing_date":"2026-08-03","report_date":"2026-08-03","primary_document":"vnth_8k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1497130/000190359626000287/vnth_8k.htm"},"events":[{"id":23191,"run_id":20987,"accession_number":"0001903596-26-000287","anchor_item_number":null,"event_type":"ma_activity","event_domain":"operational","is_material":true,"confidence":0.92,"summary":"The filing discloses entry into a Share Exchange and Acquisition Agreement on July 29, 2026, whereby Neptune Engineering Limited will become a 100% wholly owned subsidiary of Nano Mobile Healthcare. The Company will receive all issued and outstanding share capital of Neptune (10,000 ordinary shares) in exchange for 20 million post-restructuring shares of common stock to Neptune's shareholders. This constitutes a material acquisition under Item 1.01, with board approval from both parties and customary representations, warranties, and covenants. The transaction also triggers significant executive changes (Item 5.02), but the primary disclosed event is the M\u0026A activity itself.","company_name":"Nano Mobile Healthcare, Inc.","ticker":null,"filing_date":"2026-08-03","form":"8-K","submitted_at":null,"items":null}],"classifications":[{"id":23358,"accession_number":"0001903596-26-000287","item_number":null,"item_title":null,"event_type":"ma_activity","event_domain":"operational","is_material":true,"confidence":0.92,"reasoning":"The filing discloses entry into a Share Exchange and Acquisition Agreement on July 29, 2026, whereby Neptune Engineering Limited will become a 100% wholly owned subsidiary of Nano Mobile Healthcare. The Company will receive all issued and outstanding share capital of Neptune (10,000 ordinary shares) in exchange for 20 million post-restructuring shares of common stock to Neptune's shareholders. This constitutes a material acquisition under Item 1.01, with board approval from both parties and customary representations, warranties, and covenants. The transaction also triggers significant executive changes (Item 5.02), but the primary disclosed event is the M\u0026A activity itself.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-04T00:43:40.284325+00:00","company_name":"Nano Mobile Healthcare, Inc.","ticker":null,"filing_date":"2026-08-03"}]}